论文部分内容阅读
评价ＣＰＺ／ＳＢＴ对３４８株医院感染细菌的抗菌活性，并与ＣＰＺ等其他抗生素进行对比。３４８菌株的产β－内酰胺酶率为６０．３％。纸片法药敏试验结果表明，细菌对ＣＰＺ／ＳＢＴ的敏感率（８８．８％）明显高于ＣＰＺ（７１．６％）、ＣＴＸ（６１．８％）和ＣＡＺ（７１．０％）（Ｐ＜０．０５或０．０１），而略低于ＩＭＰ（９２．５％）（Ｐ＞０．０５）。又在革兰阴性肠杆菌科细菌、革兰阴性不发酵杆菌和革兰阳性球菌中分别比较各抗生素的抗菌活性，亦都以对ＣＰＺ／ＳＢＴ和ＩＭＰ的敏感率高于其他各药而ＣＰＺ／ＳＢＴ和ＩＭＰ之间无明显差异。从而提示ＣＰＺ／ＳＢＴ作为一种新型广谱抗生素，对治疗产β－内酰胺酶耐药菌株引起的严重感染将具有良好的前景。
The antimicrobial activity of CPZ / SBT against 348 hospital-acquired bacteria was evaluated and compared with other antibiotics such as CPZ. 348 strains produced β-lactamase rate of 60.3%. Susceptibility of bacteria to CPZ / SBT (88.8%) was significantly higher than that of CPZ (71.6%), CTX (61.8%) and CAZ (71.0%) ( P <0.05 or 0.01), but slightly lower than IMP (92.5%) (P> 0.05). The antibacterial activity of each antibiotic was also compared among Gram-negative Enterobacteriaceae, Gram-negative non-fermentative bacillus and Gram-positive cocci. The sensitivity of CPZ / SBT and IMP to CPZ / There was no significant difference between SBT and IMP. It suggested that CPZ / SBT as a new broad-spectrum antibiotics will have a good prospect for the treatment of severe infections caused by β-lactamase-resistant strains.